Paul  Varki net worth and biography

Paul Varki Biography and Net Worth

Insider of Avalo Therapeutics

Mr. Varki brings 25 years of experience providing counsel in the pharmaceutical and biotech industry. Mr. Varki most recently served as US General Counsel at Idorsia Pharmaceuticals US Inc. He was previously Head of Legal at Amarin Corporation plc, SVP General Counsel, Chief Compliance Officer, and Corporate Secretary at both Braeburn Pharmaceuticals and Egalet Pharma. Prior to that, Mr. Varki spent 12 years at GSK, with increasing levels of responsibility; Counsel-US Pharmaceuticals, Senior Counsel-Global Vaccines and Biologics, and Assistant General Counsel-Global Research and Development. Mr. Varki also has prior experience practicing FDA law with Reed Smith LLP, a global private law firm in Washington DC, and as a regulatory counsel with the FDA Center for Drug Evaluation and Research (CDER). He earned his JD from Temple University School of Law, earned his Master of Public Health (MPH) from George Washington University School of Public Health and received his BA from the College of William and Mary.

What is Paul Varki's net worth?

The estimated net worth of Paul Varki is at least $73.59 thousand as of May 6th, 2026. Varki owns 3,634 shares of Avalo Therapeutics stock worth more than $73,589 as of May 11th. This net worth evaluation does not reflect any other assets that Varki may own. Learn More about Paul Varki's net worth.

How do I contact Paul Varki?

The corporate mailing address for Varki and other Avalo Therapeutics executives is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. Avalo Therapeutics can also be reached via phone at (410) 522-8707 and via email at [email protected]. Learn More on Paul Varki's contact information.

Has Paul Varki been buying or selling shares of Avalo Therapeutics?

During the last ninety days, Paul Varki has sold $1,514,020.71 in Avalo Therapeutics stock. Most recently, Paul Varki sold 75,063 shares of the business's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a transaction totalling $1,514,020.71. Following the completion of the sale, the insider now directly owns 3,634 shares of the company's stock, valued at $73,297.78. Learn More on Paul Varki's trading history.

Who are Avalo Therapeutics' active insiders?

Avalo Therapeutics' insider roster includes Mittie Doyle (Insider), Schond Greenway (CFO), Christopher Sullivan (CAO), Paul Varki (Insider), and H. Wilkins (Insider). Learn More on Avalo Therapeutics' active insiders.

Are insiders buying or selling shares of Avalo Therapeutics?

In the last year, insiders at the sold shares 8 times. They sold a total of 138,078 shares worth more than $2,501,346.37. The most recent insider tranaction occured on May, 6th when insider Paul Varki sold 75,063 shares worth more than $1,514,020.71. Insiders at Avalo Therapeutics own 4.5% of the company. Learn More about insider trades at Avalo Therapeutics.

Information on this page was last updated on 5/6/2026.

Paul Varki Insider Trading History at Avalo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/6/2026Sell75,063$20.17$1,514,020.713,634View SEC Filing Icon  
See Full Table

Paul Varki Buying and Selling Activity at Avalo Therapeutics

This chart shows Paul Varki's buying and selling at Avalo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avalo Therapeutics Company Overview

Avalo Therapeutics logo
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $20.25
Low: $19.80
High: $22.02

50 Day Range

MA: $15.61
Low: $12.86
High: $22.87

2 Week Range

Now: $20.25
Low: $3.39
High: $24.27

Volume

2,848,904 shs

Average Volume

997,546 shs

Market Capitalization

$540.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78